Noninvasive Brain Tumor Subtyping And Follow-up By In Vivo MR Spectroscopy

Metabolic alterations are a hallmark of cancer and could represent vulnerable therapeutic targets. In certain tumors, altered metabolism can be caused by peculiar genetic mutations associated with high prognostic value. Notably, noninvasive detection of IDH1/2 mutations in gliomas via D-2-hydroxyglutarate (2HG) quantification, or SDH mutations in endocrine tumors via succinate quantification, significantly help patient stratification and choice of optimal treatment strategies. In this presentation, I will show how tumor subtyping and response to treatment can be predicted noninvasively using advanced in vivo Magnetic Resonance Spectroscopy methods, potentially speeding up the clinical workflow. The role of 2HG in the upcoming IDH-inhibitor treatment era, as well as the clinical potential of recently discovered molecules such as cystathionine will also be discussed.

Dr Francesca Branzoli

The lecture will be held in Sitem-insel Auditorium E0.211 (ground floor, Auditorium Felix Frey ),

Freiburgstr. 3, Bern followed by an Apéro and discussion and networking, and

Via zoom https://unibe-ch.zoom.us/j/66256483922?pwd=aE1kTFg5aUZza1JmWEJxZDVsdnV5dz09

Please feel free to spread the word to anybody potentially interested.

For further info please contact: karin.zwygart@insel.ch and jessica.bastiaansen@unibe.ch